Natera (NASDAQ:NTRA) Director Sells $24,242.62 in Stock

Natera, Inc. (NASDAQ:NTRA) Director Gail Boxer Marcus sold 122 shares of Natera stock in a transaction that occurred on Monday, November 3rd. The shares were sold at an average price of $198.71, for a total value of $24,242.62. Following the completion of the transaction, the director owned 5,762 shares in the company, valued at $1,144,967.02. This trade represents a 2.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Natera Price Performance

Shares of NTRA stock traded down $1.78 during midday trading on Tuesday, hitting $196.45. The company had a trading volume of 1,848,962 shares, compared to its average volume of 1,140,512. The company’s 50 day simple moving average is $175.77 and its 200 day simple moving average is $162.77. Natera, Inc. has a 52-week low of $122.08 and a 52-week high of $203.23. The stock has a market cap of $26.96 billion, a price-to-earnings ratio of -102.85 and a beta of 1.75.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.14). Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The firm had revenue of $546.60 million during the quarter, compared to analysts’ expectations of $476.84 million. During the same quarter last year, the business earned ($0.30) earnings per share. The business’s quarterly revenue was up 32.2% on a year-over-year basis. Natera has set its FY 2025 guidance at EPS. Analysts anticipate that Natera, Inc. will post -1.49 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. Stephens reaffirmed an “overweight” rating and issued a $183.00 target price on shares of Natera in a report on Friday, August 15th. Wells Fargo & Company started coverage on shares of Natera in a report on Monday, September 22nd. They issued an “equal weight” rating and a $175.00 target price on the stock. Barclays reaffirmed an “overweight” rating and issued a $210.00 price objective (up previously from $190.00) on shares of Natera in a report on Friday, August 8th. Morgan Stanley reaffirmed an “overweight” rating and issued a $195.00 price objective on shares of Natera in a report on Sunday, August 10th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $220.00 price objective (up previously from $210.00) on shares of Natera in a report on Monday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $194.89.

Institutional Investors Weigh In On Natera

Several institutional investors have recently modified their holdings of NTRA. Price T Rowe Associates Inc. MD boosted its stake in shares of Natera by 56.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,537,743 shares of the medical research company’s stock worth $1,490,144,000 after acquiring an additional 3,795,315 shares in the last quarter. JPMorgan Chase & Co. boosted its position in Natera by 44.3% during the second quarter. JPMorgan Chase & Co. now owns 10,625,785 shares of the medical research company’s stock worth $1,795,125,000 after purchasing an additional 3,263,822 shares in the last quarter. Norges Bank purchased a new stake in Natera during the second quarter worth $277,749,000. Nuveen LLC purchased a new stake in Natera during the first quarter worth $113,375,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Natera by 140.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,253,790 shares of the medical research company’s stock worth $177,298,000 after purchasing an additional 732,156 shares in the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.